PDUFA Renewal Negotiations: Industry On Offense, But Pricing Debate Could Hurt
This article was originally published in The Pink Sheet Daily
Executive Summary
Unlike in previous years, industry went into the current round of reauthorization talks with clear reform goals, but Congress could shift focus to drug pricing.